Anshika Jangra1,2, Seung Ah Choi1,2, Eun Jung Koh1,2, Youn Joo Moon1,2, Kyu-Chang Wang1,2, Ji Hoon Phi1,2, Ji Yeoun Lee1,2,3, Seung-Ki Kim4,5. 1. Division of Pediatric Neurosurgery, Seoul Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea. 2. Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. 3. Department of Anatomy, Seoul National University College of Medicine, Seoul, South Korea. 4. Division of Pediatric Neurosurgery, Seoul Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea. nsthomas@snu.ac.kr. 5. Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. nsthomas@snu.ac.kr.
Abstract
PURPOSE: Moyamoya disease (MMD) is one of the most common causes of pediatric stroke. We found defective angiogenic function and downregulation of retinaldehyde dehydrogenase 2 (RALDH2) in MMD endothelial colony-forming cells (ECFCs). Downregulation of RALDH2 mRNA was caused by decreased binding of acetyl-histone H3 (Ac-H3) to the RALDH2 promoter. In this study, we evaluated the feasibility of using a histone deacetylase (HDAC) inhibitor, panobinostat, to upregulate RALDH2 expression and restore the angiogenic potential of MMD ECFCs. METHODS: ECFCs from healthy normal controls and patients with MMD were isolated and characterized. After panobinostat treatment, western blot, tube formation, and chromatin immunoprecipitation (ChIP) assays were conducted in vitro. A matrigel plug assay was performed in vivo. RESULTS: Panobinostat increased the levels of Ac-H3 and Ac-H4 in both normal and MMD ECFCs but was much more effective in MMD ECFCs. Increased expression of RALDH2 by panobinostat was observed only in MMD ECFCs. Panobinostat increased the tube formation of both normal and MMD ECFCs in vitro and in vivo, but the effect was greater with MMD ECFCs. CONCLUSIONS: We demonstrated that panobinostat increases the angiogenic ability of MMD ECFCs by regulating RALDH2 acetylation. Our results suggest that panobinostat might be a potent therapeutic option for MMD patients.
PURPOSE:Moyamoya disease (MMD) is one of the most common causes of pediatric stroke. We found defective angiogenic function and downregulation of retinaldehyde dehydrogenase 2 (RALDH2) in MMD endothelial colony-forming cells (ECFCs). Downregulation of RALDH2 mRNA was caused by decreased binding of acetyl-histone H3 (Ac-H3) to the RALDH2 promoter. In this study, we evaluated the feasibility of using a histone deacetylase (HDAC) inhibitor, panobinostat, to upregulate RALDH2 expression and restore the angiogenic potential of MMD ECFCs. METHODS: ECFCs from healthy normal controls and patients with MMD were isolated and characterized. After panobinostat treatment, western blot, tube formation, and chromatin immunoprecipitation (ChIP) assays were conducted in vitro. A matrigel plug assay was performed in vivo. RESULTS:Panobinostat increased the levels of Ac-H3 and Ac-H4 in both normal and MMD ECFCs but was much more effective in MMD ECFCs. Increased expression of RALDH2 by panobinostat was observed only in MMD ECFCs. Panobinostat increased the tube formation of both normal and MMD ECFCs in vitro and in vivo, but the effect was greater with MMD ECFCs. CONCLUSIONS: We demonstrated that panobinostat increases the angiogenic ability of MMD ECFCs by regulating RALDH2 acetylation. Our results suggest that panobinostat might be a potent therapeutic option for MMD patients.
Authors: Young Jun Seo; Yeona Kang; Lisa Muench; Alicia Reid; Shannon Caesar; Logan Jean; Florence Wagner; Edward Holson; Stephen J Haggarty; Philipp Weiss; Payton King; Pauline Carter; Nora D Volkow; Joanna S Fowler; Jacob M Hooker; Sung Won Kim Journal: ACS Chem Neurosci Date: 2014-05-21 Impact factor: 4.418
Authors: Young Eun Lee; Seung Ah Choi; Pil Ae Kwack; Hak Jae Kim; Il Han Kim; Kyu-Chang Wang; Ji Hoon Phi; Ji Yeoun Lee; Sangjoon Chong; Sung-Hye Park; Kyung Duk Park; Do Won Hwang; Kyeung Min Joo; Seung-Ki Kim Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300
Authors: Francesca Tinelli; Sara Nava; Francesco Arioli; Gloria Bedini; Emma Scelzo; Daniela Lisini; Giuseppe Faragò; Andrea Gioppo; Elisa F Ciceri; Francesco Acerbi; Paolo Ferroli; Ignazio G Vetrano; Silvia Esposito; Veronica Saletti; Chiara Pantaleoni; Federica Zibordi; Nardo Nardocci; Maria Luisa Zedde; Alessandro Pezzini; Vincenzo Di Lazzaro; Fioravante Capone; Maria Luisa Dell'Acqua; Peter Vajkoczy; Elisabeth Tournier-Lasserve; Eugenio A Parati; Anna Bersano; Laura Gatti Journal: Int J Mol Sci Date: 2020-08-11 Impact factor: 5.923